Triple threat: radiation, chemo, and immunotherapy join forces against advanced rectal cancer
NCT ID NCT06787183
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2 trial is testing whether a short course of radiation followed by two cycles of chemotherapy (CAPOX) plus an experimental immunotherapy drug (QL1706) can help people with rectal cancer that has spread to the liver. The study will enroll 42 adults aged 18-75 who have not had prior treatment. The main goal is to see how long the cancer stays under control, while also monitoring side effects.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- QL1706 (a bispecific antibody targeting PD-1 and CTLA-4), capecitabine, oxaliplatin, and short-course radiotherapy
- What this could lead to
- If successful, this combination could offer a new, more effective treatment option for people with rectal cancer that has spread to the liver, potentially improving how long they live without the cancer growing.
- What could go wrong
- This is a small, early-phase trial (42 people) with no control group, so results may not apply broadly. The combination of radiation, chemotherapy, and immunotherapy can cause significant side effects, including severe immune-related reactions.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LOCALLY ADVANCED RECTAL CANCER WITH LIVER METASTASES are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Fujian Cancer Hospital
RECRUITINGFuzhou, Fujian, 350014, China
-
Fuzhou First General Hospital
NOT_YET_RECRUITINGFuzhou, Fujian, 350004, China